Clinical Trial Portfolio Alerts: Then What?

The myriad use cases of clinical trial information is an embarrassment of riches. Consider these:

  • Executive: Keep an eye on competitor trials; starting and changes to trials can signal changes in the status and health of a trial and a portfolio.
  • Clinician: Watch for new trials that may be applicable to patients.
  • Drug developer: Discover new applications of drugs, targets, and biomarkers in your portfolio. Learn from the knowledge and strategies of competitors.
  • Clinical researcher: Watch for new trials to connect with sponsors and market your services.
  • Investor: Monitor changes  to a trial to anticipate market moves of a stock.

Keeping up with clinical trials information is required to maintain a competitive advantage. If your competitor has information and you don't, you are at a disadvantage.

But, who has time for searching and collating at And, browser bookmarking and RSS feeds are clumsy. What can you do with a weekly Excel listing for 1 query? How would you handle 20? Or, 100?

Responding to these requirements, we are rolling out "Clinical Trial Portfolio Alerts". to address these problems.

The service will keep track of not just one, but many searches and provide a formatted email summarizing activity of the entire portfolio. Tens or hundreds of queries can be submitted just once and continuously monitored. At the frequency of your choosing (nightly, weekly, monthly, quarterly) we will send a nicely formatted, mobile-ready email summarizing new, changed, and total number of trials for each collection.  

Screen Shot 2018-08-31 at 12.46.37 PM.png

Then what?

  • Drill into the details of new trials and see what is being studied
  • Evaluate changes to the history to see if a changing trial may be in trouble
  • See who is collaborating on new studies and evaluate their portfolio
  • Contact the trial liaison or investigators at the nearest site
  • Evaluate the enrollment rate and timeline of the trial to assess its risk
  • Identify new uses for drugs, targets, and biomarkers



Photo by rawpixel on Unsplash